

Claims:

1. A tablet comprising celecoxib and ciprofloxacin or a pharmaceutically acceptable salt thereof, and low viscosity hydroxypropyl methylcellulose having a viscosity of between 2 cP and 150 cP, when measured as a 2% solution in water at 20°C.
2. The tablet according to claim 1 wherein the pharmaceutically acceptable salt of ciprofloxacin is ciprofloxacin HCl.
3. The tablet according to claim 1 wherein the hydroxypropyl methylcellulose has methoxyl substitution of between 28.0% and 30.0% and hydroxypropoxyl substitution of between 7.0% and 12.0%.
4. The tablet according to claim 1 wherein the hydroxypropyl methylcellulose has methoxyl substitution of between 19.0% and 24.0%, and hydroxypropoxyl substitution of between 7.0% and 12.0%.
5. The tablet according to claim 1 wherein the hydroxypropyl methylcellulose is present in an amount of between 3% and 10% by weight of the tablet.
6. The tablet according to claim 5 wherein the hydroxypropyl methylcellulose is present in an amount of 5% by weight of the tablet.
7. The tablet according to claim 1 wherein the hydroxypropyl methylcellulose is present in an amount of between 4% and 15% by weight relative to the weight of the active ingredients, celecoxib and a pharmaceutically acceptable salt of ciprofloxacin, in the tablet.
8. The tablet according to claim 7 wherein the hydroxypropyl methylcellulose is present in an amount of between 6% and 8% by weight relative to the weight of the active ingredients.
9. The tablet according to claim 1 wherein the tablet comprises an extragranular component and an intragranular component, wherein the hydroxypropyl methylcellulose is present in the extragranular component.
10. The tablet according to claim 9 wherein the celecoxib and the pharmaceutically acceptable salt of ciprofloxacin are present in the intragranular component.

11. The tablet according to claim 1, and further comprising a filler, selected from the group consisting of soluble, non soluble and a mixture of soluble and non soluble fillers.
12. The tablet according to claim 11 wherein the filler is microcrystalline cellulose, lactose, mannitol, or a combination thereof.
13. The tablet according to claim 1 wherein low viscosity hydroxypropyl methylcellulose has a viscosity of 50 cP, when measured as a 2% solution in water at 20°C.
14. The tablet according to claim 1 wherein the ratio of weight of celecoxib to the weight of the ciprofloxacin free base is between 1:1 to 1:100.
15. The tablet according to claim 14 wherein the ratio of weight of celecoxib to the weight of the ciprofloxacin free base is 1:10-1:25.
16. The tablet according to claim 15 wherein the ratio of weight of celecoxib to the weight of the ciprofloxacin free base is 1:10.
17. The tablet according to claim 1 wherein between 10% and 30% ciprofloxacin and celecoxib is released at 1 hour, and between 30% and 70% ciprofloxacin and celecoxib is released at 4 hours, and more than 85% ciprofloxacin and celecoxib is released at 12 hours, when placed in 900 ml of acetate buffer pH 4.5, in a Type II apparatus, at 75 RPM, 37°C comprising 1% SLS.
18. The tablet according to claim 1 wherein upon administering the tablet to a human subject for 7 days with food and water, the Tmax for celecoxib in the subject's serum is within the range of between 80% and 125% of the Tmax for ciprofloxacin in the subject's serum.
19. A process for manufacture of the tablet according to any one of the previous claims comprising:
- forming granules comprising celecoxib and ciprofloxacin or a pharmaceutically acceptable salt thereof;
 - adding a low viscosity hydroxypropyl methylcellulose having a viscosity of less than 150 cP, when measured as a 2% solution in water at 20°C to the granules, to form a mixture; and
 - compressing the mixture to form a tablet.

20. Use of a tablet according to any one of the previous claims for the manufacture of a medicament for treatment of amyotrophic lateral sclerosis (ALS) in a patient in need thereof.